Cannabigerol (CBG) is a rising star within the hemp industry, tipped to follow in the footsteps of CBD as the next non-psychoactive cannabinoid to dominate the low-THC consumer market.
Recently, the lesser-known cannabinoid has gained a foothold in the marketplace as companies such as Avicanna Inc. continue to propel research into the compound’s therapeutic promise.
“We are confident about the prospects of CBG as an active ingredient in our consumer product lines and also its potential in our drug development platforms in isolation and in synergy with other cannabinoids. Our research teams around the world are already incorporating CBG into several oral and topical formulations and are in parallel conducting in vitro and in vivo studies to better understand its potential and efficacy for specific indications”, stated Dr. Justin Grant, Avicanna’s Executive Vice President of Scientific Affairs.
What is CBG?
CBG is often likened to the more familiar CBD, and at the surface level, they do appear to have similar properties. Both have been seen to exhibit promising anti-inflammatory properties, fight pain, and combat nausea.
Read full article here: https://prohibitionpartners.com/2020/05/15/hemp-and-cbg-what-will-the-2020-consumer-look-like/